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Abstract
Background: Tacrolimus (FK-506) is an immunosuppressant that binds to a specific immunophilin,
resulting in the suppression of the cellular immune response during transplant rejection. Except for
some alterations in the spermatozoa, testicular morphological alterations have not been described
in rats treated with tacrolimus. In the present study, we purpose to evaluate if the treatment with
tacrolimus at long term of follow-up interferes in the integrity of the seminiferous tubules.
Methods: Rats aging 42-day-old received daily subcutaneous injections of 1 mg/kg/day of
tacrolimus during 30 (T-30) and 60 (T-60) days; the rats from control groups (C-30 and C-60)
received saline solution. The left testes were fixed in 4% formaldehyde and embedded in glycol
methacrylate for morphological and morphometric analyses while right testes were fixed in Bouin's
liquid and embedded in paraffin for detection of cell death by the TUNEL method. The epithelial
and total tubular areas as well as the stages of the seminiferous epithelium and the number of
spermatocytes, spermatids and Sertoli cells (SC) per tubule were obtained.
Results: In the treated groups, seminiferous tubules irregularly outlined showed disarranged
cellular layers and loss of germ cells probably due to cell death, which was revealed by TUNEL
method. In addition to germ cells, structural alterations in the SC and folding of the peritubular
tissue were usually observed. The morphometric results revealed significant decrease in the
number of SC, spermatocytes, spermatids and significant reduction in the epithelial and total
tubular areas.
Conclusion: Tacrolimus induces significant histopathological disorders in the seminiferous
tubules, resulting in spermatogenic damage and reduction in the number of Sertoli cells. A careful
evaluation of the peritubular components will be necessary to clarify if these alterations are related
to the effect of FK-506 on the peritubular tissue.
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The immunosuppressive therapy in organ transplant
recipients has included the use of calcineurin inhibitors
such as tacrolimus (FK-506) and cyclosporine [1].
Although the mechanism of action of tacrolimus is similar
to that of cyclosporine, tacrolimus is 10 to 100 times more
potent and has been referred as useful therapeutic option
for the transplant recipients. Tacrolimus is a macrolide
immunosuppressant isolated from fermentation broth of
Streptomyces tsukubaensis [2]. This drug binds to a specific
immunophilin, called FKBP12, forming a complex in the
lymphocytes that inhibits calcineurin, a Ca2+- and cal-
modulin-dependent serine/threonine phosphatase. Cal-
cineurin plays a critical role in interleukin (IL)-2 promoter
induction after T-cell activation [3]. Thus, the tacrolimus-
FKBP12 complex prevents dephosphorylation of the cyto-
plasmic subunit of nuclear factor of activated T-cell (NF-
ATc) by calcineurin, resulting in the suppression of IL-2
transcription and inhibition of the cellular immune
response during transplant rejection [1]. High levels of
tacrolimus in the blood are observed 2 hours after oral
administration [3,4]. This drug (98%) circulates in the
blood, bound to plasma proteins, such as albumin, lipo-
proteins and globulins [4,5] and accumulates in several
tissues such as lung, spleen, kidney, heart, pancreas, mus-
cle and liver [1,3].
Some adverse effects associated to tacrolimus treatment
have been related in the treated patients, such as nephro-
toxicity, neurotoxicity, Diabetes mellitus, gastrointestinal
disturbances and hypertension [1,6,7]. The inhibition of
calcineurin leads to decrease in the intracellular transcrip-
tion of insulin by the pancreatic cells. Thus, hyperglicemia
and post-transplant Diabetes mellitus (PTDM) are the most
common metabolic diseases caused by calcineurin inhib-
itors such as FK-506 [1,8]. The nephrotoxicity has been
associated to vasoconstriction, reduction in the glomeru-
lar filtration [9] and histopathological alterations, such as
hyaline arteriolopathy, striped interstitial fibrosis and
tubular atrophy [10-12].
Studies focusing the effects of calcineurin inhibitor immu-
nosuppressants, mainly tacrolimus, on the reproductive
system are scarce in the literature. Some testicular effects
have been demonstrated in rats treated with the other cal-
cineurin inhibitor immunosuppressant – cyclosporine.
Among the effects, reduction in the testicular weight [13],
decrease in the diameters of the seminiferous tubules [13-
16], decrease in the number of spermatocytes at stage VII
[17] and desquamation of round spermatids [16,17] have
been reported. Additionally, testicular ultrastructural
analyses revealed the presence of damaged spermatids, as
well as disconnection of the head from the tail of sperma-
tozoa and abnormal development of flagella [16]. In con-
trast to cyclosporine, testicular alterations have not been
found in tacrolimus-treated rats for 2 weeks [18,19].
Moreover, the plasma levels of testosterone [18,19] and
LH [18] were normal after tacrolimus treatment. How-
ever, the number and motility of spermatozoa reduced
and the number of live fetus and the embryonic implan-
tation index reduced after mating of the treated male rats
with untreated female rats [19]. Since these authors have
observed degenerative germ cells in the lumen of epidi-
dymis, it has been suggested that the quantitative and
functional alterations in the spermatozoa resulted from
the effect of tacrolimus in the epididymis rather than the
seminiferous epithelium. According to the transplanted
organ, the period of therapy in the patients receiving tac-
rolimus-based immunosuppression varies from 1 to 5
years of follow-up. In the present study, we purpose to
evaluate the structural integrity of the seminiferous
tubules in rats treated with tacrolimus at long term (30
and 60 days) of follow-up.
Methods
Animals and treatment
Twenty Holtzman male rats (Rattus norvegicus albinus)
aging 42 day-old (weighing around 160 g) were main-
tained in plastic cages under 12 h light/12 h dark cycle at
controlled temperature (23 ± 2°C), with water and food
provided ad libitum. The animal care and the experimental
procedures were conducted following the national law on
animal use. This protocol was approved by the Ethical
Committee for Animal Research of São Paulo Federal Uni-
versity, Brazil (UNIFESP/EPM).
The animals were distributed into four groups: two con-
trol groups (C-30 and C-60) and two tacrolimus (Prograf®
– Janssen Cilag, São José dos Campos, SP, Brazil) groups
(T-30 and T-60). The rats from T-30 and T-60 were
weighed weekly and received daily subcutaneous injec-
tions of 1 mg/kg/day of tacrolimus [20] during 30 and 60
days, respectively. This dosage provides plasma peak and
through levels of tacrolimus of approximately 11.2 ng/ml
[21-23] and has been reported to be immunosuppressive
and clinically relevant, resulting in a consistent response
[20].
The animals from control groups received subcutaneous
injections of saline solution during the same periods.
Histological procedures
The rats were anaesthetized with 80 mg/Kg of body weight
of Ketamine (Francotar®; Virbac do Brazil Ind. e Com.
Ltda., São Paulo, SP, Brazil). The testes were removed,
weighed and the rats were killed by an overdose of Keta-
mine. The right testes were fixed in Bouin's liquid, embed-
ded in paraffin and the sections were submitted to TUNEL
method for detection of cell death. The left testes were
fixed in 4% formaldehyde (prepared from paraformalde-
hyde), at pH 7.4 with 0.1 M sodium phosphate, embed-
ded in glycol methacrylate (Historesin-Embedding Kit,Page 2 of 9
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hematoxylin and eosin – HE [24] for morphometric anal-
yses.
Morphometric analyses
Seminiferous tubules cross sections were randomly cho-
sen in three non-serial sections per animal, totalizing 100
tubules/animal. Taking into account that the epithelial
area can be altered without to affect, necessarily, the total
tubular area, these two areas were evaluated. In each
tubule, the epithelial area and the total tubular area were
measured by using a 25-point integrating eyepiece
attached to a light binocular microscope (Carl Zeiss, Ger-
many). The number of points upon the seminiferous epi-
thelium and upon the whole seminiferous tubule
(epithelium and lumen) was counted at ×250. Thus, the
epithelial and total tubular areas were obtained by multi-
plying the number of points by the area of each point
[25].
Based on the method of classification previously
described [26,27], the seminiferous tubules were classi-
fied into four categories according to the total area: a)
reduced (measuring 19 × 103 μm2 – 51 × 103 μm2), b)
small (measuring 51 × 103 μm2 – 83 × 103 μm2), c)
medium (83 × 103 μm2 – 115 × 103 μm2) and d) large
(measuring 115 × 103 μm2 – 147 × 103 μm2). The fre-
quency of tubules according to these categories was
obtained in all groups.
The identification of the stages of the seminiferous epithe-
lium in the rat has been greatly improved when the testes
are embedded in glycol methacrylate [28]. Thus, during
the morphometric analysis, the stages I to V; VI to VIII; IX;
X; XI to XIV [29] were identified and the frequency of
tubules according to these stages was obtained. In the
treated animals, only seminiferous tubules whose stages
could be identified were computed.
The number of germ cells and Sertoli cells were quantified
in cross sections of seminiferous tubules. The number of
Sertoli cells per tubule was computed in 30 tubules/ani-
mal [30] using a light binocular microscope at ×500 (Carl
Zeiss, Germany). Only Sertoli cells exhibiting typical mor-
phological nuclear features and evident nucleolus were
quantified. The number of spermatocytes and spermatids
(round and elongate) was quantified in 10 tubules/ani-
mal [17]. Since the number of germ cells in tubular sec-
tions at stages I-VIII is different from those at stages IX-
XIV, five tubules at stage I-VIII and five tubules at stage IX-
XIV per animal were counted.
TUNEL method
For detection of DNA breaks in the dying germ cells, we
used the TUNEL (Terminal deoxynucleotidyl transferase-
mediated dUTP Nick-End Labeling) method. The Apop
Tag Peroxidase kit (Chemicon International, Chemicula,
CA, USA) for in situ apoptosis detection was used [31].
The sections were treated with 3% hydrogen peroxide to
block endogenous peroxidase and DNA end-labeling was
performed by the incubation of sections in TdT enzyme.
Subsequently, the sections were incubated with anti-dig-
oxigenin-peroxidase antibodies; the reaction was revealed
by 0.06% 3.3-diaminobenzidine (DAB) and the sections
were counterstained with Carazzi's hematoxylin. Sections
of mammary gland provided by the manufacturer of the
kit were used as positive controls for the TUNEL method.
Testicular sections, used as negative controls, were incu-
bated in a TdT enzyme-free solution.
Statistical analysis
Statistical analysis of morphometric data was performed
using the software SigmaStat 3.2. According to the distri-
bution of data, the differences between groups were ana-
lyzed by the t-Student test or the Mann-Whitney test. The
significance level accepted was p ≤ 0.05.
For assessment of time-dependent action of tacrolimus,
the total tubular area was analyzed by two-way ANOVA
test.
Results
Body and testicular weight
According to table 1, the body weight of animals from T-
30 and T-60 reduced significantly. A significant reduction
in the absolute testicular weight was observed only in T-
60 group.
Light microscopy
In the testicular sections of rats from C-30 and C-60, the
seminiferous tubules with normal shape showed germ
cells organized in concentric layers and the tubular lumen
was usually empty. Typical triangle/ovoid Sertoli cell
nuclei exhibiting evident nucleolus were observed in the
basal compartment adjacent to peritubular tissue. The
peritubular tissue surface was rectilinear and showed sev-
eral nuclei of peritubular cells (Figs. 1A and 1B). In the tes-
ticular sections of tacrolimus-treated rats (T-30 and T-60),
seminiferous tubules irregularly outlined showing disar-
ranged epithelial layers and lumen filled with detached
Table 1: Body weight (BW) and absolute testicular weight (TW) 
of animals from control (C-30 and C-60) and tacrolimus (T-30 
and T-60) groups
Animals BW (g) TW (g)
C-30 330 ± 34 1.66 ± 0.10
T-30 265 ± 20* 1.58 ± 0.15
C-60 423 ± 21 1.85 ± 0.10
T-60 310 ± 22* 1.65 ± 0.05*
*p < 0.05(statistically significant)Page 3 of 9
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in the atrophied tubules (Figs. 1C and 1D). In the altered
tubules, the Sertoli cell nuclei exhibited irregular shape
and strongly stained chromatin. Adjacent to these altered
nuclei, vacuolar spaces were often observed (Figs. 2A, 2B,
2D and 2E). Moreover, nuclei of Sertoli cell displaced
from their normal position to the adluminal compart-
ment were found in tubules at different stages (Figs. 2C,
2D and 2F). Disorganized round and elongate spermatids
irregularly positioned in the basal compartment and
intraepithelial spaces indicating loss of germ cells were
found (Figs. 2B, 2C, 2E and 2F). Surrounding the altered
epithelium, the peritubular tissue was irregularly outlined
and, sometimes, intensely folded (Figs. 2C and 2F).
The testicular sections of rats from control groups submit-
ted to TUNEL method revealed scarce TUNEL-positive
germ cells (Fig. 3A). Otherwise, TUNEL-labeling was usu-
ally observed in spermatogonia, leptotene to pachytene
spermatocytes as well as in round and elongate sperma-
tids of the tacrolimus-treated rats (Figs. 3B–3G). TUNEL-
positive giant multinucleated cells derivative from round
spermatids were also found (Fig. 3G).
The sections of mammary gland, used as positive control,
showed numerous TUNEL-positive cells while none posi-
tivity was observed in the testicular sections used as nega-
tive control (data not illustrated).
Morphometric results
A significant reduction in the tubular and epithelial areas
was observed in the testes of rats treated with tacrolimus
during 30 and 60 days, in comparison to the animals from
C-30 and C-60, respectively (Table 2). The total tubular
area increased significantly under normal conditions, i.e.
from C-30 (72 days-old) to C-60 (102 days-old). How-
ever, the analysis of the effect of tacrolimus on the sem-
iniferous tubules according to the periods of treatment
revealed that the increase in the tubular area from T-30 to
T-60 was proportional to the increase of the tubular area
of control group (C-30 to C-60). There was no statistical
difference regarding the increase of the tubular area, from
30 to 60 days, between control and tacrolimus groups
(Fig. 4).
According to figure 5, the tubular area, in the control
groups (C-30 and C-60), varied from 51 × 103 μm2 to 147
× 103 μm2. After the analysis of the frequency of tubules
according to the area, the results revealed in C-30 and C-
60, respectively: a) 35% and 9% of small tubules (51 × 103
μm2 to 83 × 103 μm2), b) 54% and 40% of median tubules
(83 × 103 μm2 to 115 × 103 μm2) and c) 10% and 50% of
large tubules (measuring over 115 × 103 μm2). However,
in the treated animals (T-30 and T-60), only 58% and
74% of the total tubules, respectively, showed a similar
frequency pattern to those of the control groups. In T-30,
the frequency of median and large tubules decreased sig-
nificantly (60% and 89%, respectively), resulting in the
significant increase (100%) in the frequency of small
tubules. In T-60, the frequency of large tubules reduced
significantly (51%), resulting in the increase in the fre-
Photomicrographs of seminiferous tubules of rats from C-30 (A), C-60 (B), T-30 (C) and T-60 (D) groups stained by H.EFigure 1
Photomicrographs of seminiferous tubules of rats 
from C-30 (A), C-60 (B), T-30 (C) and T-60 (D) 
groups stained by H.E. (A and B) In the seminiferous 
tubules with normal aspect, the germ cells are organized in 
concentric layers and the tubular lumen is empty (A, aster-
isks); (B) The Sertoli cell nuclei (arrows) are positioned adja-
cent to the well defined peritubular tissue in which 
peritubular cells are observed (arrowheads). In T-30 (C) and 
T-60 (D), the altered seminiferous tubules show irregular 
shape, epithelial disorganization and detached germ cells fill-
ing the tubular lumen (asterisks). In some atrophied seminif-
erous tubules, loss of germ cells is observed (arrows). Figs. 
1A, 1C and 1D: ×110; Figs. 1B: ×330.
Figure 1Page 4 of 9
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2009, 7:19 http://www.rbej.com/content/7/1/19
Page 5 of 9
(page number not for citation purposes)
Photomicrographs of seminiferous tubules of rats from T-30 (A, B and C) and T-60 (D, E and F) group stained by H.EFigure 2
Photomicrographs of seminiferous tubules of rats 
from T-30 (A, B and C) and T-60 (D, E and F) groups 
stained by H.E. (A and B) Slightly (A) and severely (B) 
damaged tubules show vacuolar spaces (arrows) adjacent to 
Sertoli cell nuclei with irregular shape (S). In B, intraepithelial 
spaces (asterisks) due to lack of spermatocytes and sperma-
tids were observed. (C) Lack of germ cells (asterisks) is 
noted in the basal and adluminal portions. Round (thick 
arrows) and elongate (thin arrow) spermatids are abnormally 
positioned in the basal compartment. Note a single Sertoli 
cell showing dislocated nucleus (S). In the other tubule, the 
peritubular tissue is intensely folded (white arrows). (D) 
Slightly altered seminiferous tubule shows vacuolar spaces 
(arrows) adjacent to Sertoli cell nuclei. Some irregular Sertoli 
cell nuclei (S) are displaced from their original site. (E and F) 
The damaged tubules show lack of germ cells (asterisks) in 
the layers of round spermatids (St, in E), pre-leptotene (PL, 
in E) and zygotene (Z, in F) spermatocytes. In E, vacuolar 
spaces (arrows) adjacent to irregular and strongly stained 
Sertoli cell nuclei (S) are observed. In F, the peritubular tis-
sue is irregularly outlined (arrowheads). Adjacent to this 
altered tissue, the Sertoli cell nuclei are irregular and dis-
placed from their original site (S). Figs. 2A-2F: ×330.
Figure 2
Photomicrographs of seminiferous tubules of rats from C-30 (A), T-30 (B-D) and T-60 (E-G) submitted to the TUNELmethodFigure 3
Photomicrographs of seminiferous tubules of rats 
from C-30 (A), T-30 (B-D) and T-60 (E-G) submitted 
to the TUNEL-method. (A) TUNEL-positive germ cell is 
observed in the epithelium (arrow). (B-D) Primary sperma-
tocytes (thick arrows), spermatogonia (thin arrows) and 
elongate spermatids (arrowheads) are labeled by TUNEL 
method. (E-G) Spermatogonia (thin arrows), primary sper-
matocytes in different stages (thick arrows) and round sper-
matids (arrowheads) are TUNEL-positive. A giant 
multinucleated cell derivative from round spermatids (white 
arrow) is also positive. Fig. 3A: ×260; Figs. 3B-3G: ×710.
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It is important to note that in T-30 and T-60, respectively,
the treatment resulted in the frequency of 6.8% and 7.2%
of tubules measuring less than 51 × 103 μm2 (reduced
tubules), which were not found in the control groups.
According to table 2, the number of Sertoli cells/tubule
reduced significantly (18.6% and 25.4%) in the testes of
T-30 and T-60 groups, respectively. There was a significant
reduction in the number of spermatocytes and spermatids
per tubule in both tacrolimus groups. However, the reduc-
tion was more accentuated in T-30 (40% and 58%) than
in T-60 (28% and 31%).
Although the frequency of tubules at stages VI-VIII
decreased 42% in T-60, the differences regarding the fre-
quency of seminiferous tubules according to the stages
were not statistically significant between control and tac-
rolimus groups (table 3).
Discussion
Similar to previous findings [19,32], the results revealed a
significant reduction in the body weight of rats from
treated groups. Regarding the effect of tacrolimus on the
spermatogenesis, the treatment of rats with 1 or 3 mg/kg/
day of tacrolimus (FK-506) for 2 weeks leads to sperm
counts and motility decrease. However, histopathological
findings were not observed in the testes and due to the
presence of degenerative germ cells in the epididymis, it
has been concluded that spermatozoa were affected in the
epididymis, but not in the testes [19]. Spermatozoa are
originated from the spermatogenic process in the seminif-
erous epithelium which is the target tissue for the action
of many drugs. However, data regarding the effect of FK-
506 on the seminiferous tubules have not been found in
the literature. In contrast to the findings of the previous
study [19], significant alterations were observed in the
seminiferous epithelium of the rats treated with 1 mg/kg/
day of tacrolimus during 30 and 60 days. These differ-
ences could be due to the long periods of treatment eval-
uated in this study, in contrast to the short period [19].
The treatment with the immunosuppressor FK-506
induces alterations in the histoarchitecture of the seminif-
Table 2: Total tubular area (TA), seminiferous epithelium area (EA) and number of Sertoli cells (SC), spermatocytes (Sp) and 
spermatids (St) per tubule of animals from control (C-30 and C-60) and tacrolimus (T-30 and T-60) groups
Animals TA (μm2) EA (μm2) SC/tubule Sp/tubule St/tubule
C-30 88,167 ± 4,885 81,587 ± 4,766 12.36 ± 0.49 118.6 ± 9.9 228.9 ± 13.7
T-30 68,889 ± 5,739* 64,051 ± 5,712* 10.22 ± 0.38* 70.7 ± 8.9* 94.8 ± 20.0*
C-60 108,812 ± 8,044 101,580 ± 7,035 13.00 ± 0.48 102.1 ± 11.1 207.2 ± 20.2
T-60 93,376 ± 7,455* 87,478 ± 7,160* 9.70 ± 0.14* 72.8 ± 9.0* 141.6 ± 7.1*
*p < 0.05(statistically significant)
Effect of FK-506 upon total tubular area (μm2) of the seminif-erous tubules according o he time of treatmentFig re 4
Effect of FK-506 upon total tubular area (μm2) of the 
seminiferous tubules according to the time of treat-
ment.
Frequency (%) of seminiferous tubules according to the total tubular area (μm2) of animals from control (C-30 and C-60) and t crolimus (T-30 d T-60) groupsig r  5
Frequency (%) of seminiferous tubules according to 
the total tubular area (μm2) of animals from control 
(C-30 and C-60) and tacrolimus (T-30 and T-60) 
groups. *p < 0.05 (statistically significant).Page 6 of 9
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ment, abnormal positioning of disordered spermatids in
the tubular basal compartment, detached germ cells fill-
ing the tubular lumen and significant decrease in the
number of spermatocytes and spermatids. These altera-
tions resulted in a significant reduction in the epithelial
and total tubular areas after both periods of treatment
indicating that the reduction in the testicular weight is
actually due to a pathologic response to the treatment.
The treatment with cyclosporine, a calcineurin inhibitory
immunosuppressor, has caused similar testicular altera-
tions [13-16]; among them, depletion of seminiferous
epithelium due to loss of germ cells and decrease in the
tubular diameter has been described [16,17]. In the
present study, although the mean value of tubular area
reduced significantly in the treated groups, we verified
that some tubules were intensely altered, while others
were apparently normal or slightly altered. It is important
to consider that, normally, the diameters of seminiferous
tubules in cross sections are variable due to the fact that
the different segments of tubules contain cells of germinal
lineage in different stages of the seminiferous cycle [33].
For this reason, the classification of tubules in sizes
according to area was necessary to compare control and
treated groups. Based on this analysis, it was possible to
conclude that, in T-30, the reduction in the tubular area
was due to the significant reduction in the frequency of
large and median tubules, resulting in a high frequency of
small tubules. Similarly, the increased frequency of small
and median tubules was probably due to the reduction in
the frequency of large tubules in T-60. Based on this anal-
ysis, we could verify that 42% and 26% of seminiferous
tubules in T-30 and T-60, respectively, were affected by
tacrolimus, resulting in the increased frequency of small
tubules in these groups. Moreover, some tubules were
severely affected by tacrolimus, resulting in the frequency
of 7% of reduced tubules (measuring less than 51 × 103
μm2) which were inexistent in the control groups.
It has been demonstrated that cellular adhesive junctions
are important for the maintenance of tubular shape and
volume [34]. Reduction in the tubular size associated to
detachment and loss of germ cells by cell death have been
observed in the testis of rats treated with different drugs
[31,35-37]. Decrease in the number of spermatocytes [17]
and desquamation of round spermatids [16,17] have
been reported in the seminiferous tubules of rats treated
with the immunosuppressant cyclosporine. In the present
study, a significant reduction in the number of spermato-
cytes and spermatids was observed in the treated animals
(T-30 and T-60). Moreover, the TUNEL reaction was pos-
itive in several cells of the germinal lineage. Taken
together, these findings indicate that the immunosuppres-
sive treatment with tacrolimus results in the loss of germ
cells by cell death and, then, in the reduction of the tubu-
lar area.
The nutritional and structural support of germ cells is
maintained by Sertoli cells; after Sertoli cell structural
injury, the Sertoli cell-germ cell physical interaction is dis-
rupted [38] and programmed cell death is induced in the
detached germ cells [39]. In the present study, Sertoli cell
nuclei showed abnormal shape and, sometimes, were dis-
placed from their original site. Sertoli cell nuclei can be
found positioned away from the basement membrane in
normal tubules at stage VIII [28]; however, in the present
study, the Sertoli cell nuclei were dislocated from the
basal to adluminal compartment in tubules at different
stages. In addition, the number of Sertoli cells reduced sig-
nificantly in the treated groups and a probable occurrence
of Sertoli cell death should be further investigated. Thus,
it is possible that germ cell loss is due, at least in part, to
Sertoli cell damage; this is reinforced by the fact that
abnormal Sertoli cell nuclei were also found in the tubules
slightly altered by tacrolimus. Moreover, the presence of
disordered spermatids in the tubular basal compartment
suggests phagocytosis by Sertoli cells and, then, failure of
release; this abnormal condition can be caused by a pri-
mary change in the Sertoli cells [40]. Structural alterations
and apoptosis in the Sertoli cells have been related to
damage in the integrity of the peritubular tissue [30]. In
the current study, the seminiferous tubules showed irreg-
ularly outlined peritubular tissue and, in some portions,
this tissue was intensely folded. In part, these alterations
could be resulted from loss of germ cells and tubular
shrinkage. However, a possible interference of tacrolimus
on the peritubular components and, subsequently, on the
Sertoli and germ cells, should be considered and further
investigated. This hypothesis is reinforced by the fact that
the results revealed no susceptibility of the seminiferous
epithelium to FK-506, according to the stage of the sem-
iniferous cycle.
The analysis of the effect of tacrolimus on the testes
according to the periods of treatment (30 and 60 days)
leads to conclude that the effect of FK-506 was more
accentuated in the first period of treatment (T-30). In T-
30, the total tubular area reduced significantly and the
number of small tubules increased 100%, in comparison
Table 3: Frequency (%) of seminiferous tubules according to the 
stages of cycle of seminiferous epithelium of animals from 
control (C-30 and C-60) and tacrolimus (T-30 and T-60) groups
Stages C-30 T-30 C-60 T-60
I to V 44.6 ± 4.7 39.4 ± 4.6 36.2 ± 9.4 47.0 ± 6.2
VI to VIII 22.2 ± 4.4 21.0 ± 9.5 25.0 ± 13.0 14.4 ± 5.7
IX 5.8 ± 1.1 7.5 ± 2.4 6.2 ± 2.6 6.5 ± 4.2
X 2.4 ± 0.9 5.4 ± 4.1 3.8 ± 1.5 3.1 ± 1.6
XI to XIV 25.0 ± 3.0 23.0 ± 18.5 28.8 ± 4.4 29.0 ± 9.4Page 7 of 9
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ment (T-60), the frequency of these tubules did not
change significantly and the increase in the tubular area
was proportional to the increase in the tubular area of
control group (from C-30 to C-60). Under normal condi-
tions, the animals from C-30 (aging 72-day-old) contain
around 11% of large tubules, while the animals from C-
60 (aging 102-day-old) contain around 50% of large
tubules, indicating that the seminiferous tubules develop
and increase their size after 30 days. In contrast, only 24%
of large tubules were found in T-60. This reduction in the
frequency of large tubules was due to the accentuated
effect of tacrolimus in the number of spermatocytes and
spermatids, which decreased 40% and 58%, respectively,
in T-30. Thus, the effect of tacrolimus on the integrity of
the seminiferous epithelium was more accentuated in the
beginning of the treatment (T-30), resulting in a failure in
the tubular development following the treatment (T-60).
It has been demonstrated that calcineurin/NF-AT plays a
role in the function of pancreatic β-cells, including in the
cellular proliferation and synthesis of insulin [41]. Thus,
inhibition of calcineurin leads to decreased insulin tran-
scription [42,43] and, then, to post-transplantation Diabe-
tes mellitus – PTDM [44], the most known adverse effect
caused by immunosuppressive treatment with tacrolimus
[1,6,7]. The effect of diabetes on the male reproductive
system has been related to sexual impotence [45] and
male infertility [46]. Studies of rats induced to diabetes
have demonstrated testicular alterations such as tubular
atrophy due to loss of germ cells [45,47] and high fre-
quency of apoptotic germ cells [46,48]. Moreover,
ultrastructural alterations in the peritubular tissue of the
seminiferous tubules of diabetic man have also been dem-
onstrated [47]. Cases of PTDM have been reported in
patients after 1 month of the therapy with tacrolimus
[49]. Moreover, decreased tubular diameter, hyalinized
tubular walls and epithelial alterations have also been
observed in rats induced to diabetic condition for only 5
days [50]. In a previous study, high glycemic levels have
been detected in T-30 (data not published) and in T-60
[51]. The abnormalities in the glucose metabolism are
normalized after tacrolimus therapy for 180 and 240 days
[51]. Therefore, future studies are necessary to establish a
possible relationship between the tubular alterations,
observed in the treated rats, and a possible diabetogenic
effect, induced by FK-506.
Conclusion
Preventive caution must be taken during tacrolimus ther-
apy in male transplant recipients since this immunosup-
pressor induces histopathological disorders in the
seminiferous tubules, resulting in a significant decrease in
the number of germ cells. The spermatogenic damage can
be related to morphological and quantitative alterations
in the Sertoli cells. Future ultrastructural analyses of the
peritubular tissue are necessary to confirm if the epithelial
alterations are resulted from a possible effect of tac-
rolimus on the peritubular components.
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